Licensing Portfolio
CRT has an impressive range of over 200 oncology-focused projects under development and potentially available for licensing or collaboration. All are involved in the fight against cancer and include novel chemotherapeutic and biological agents, diagnostic methodologies and enabling technologies. The projects range from new targets to therapies in pre-clinical development to those in Phase I/II clinical studies.
Small Molecules
Small molecule opportunities against novel cancer targets and pathways - Drug discovery, preclinical and clinical stage opportunities available for co-development and/or licensing.
View all ›Biological Therapeutics
Patented antibodies to tumour associated cell surface markers - A diverse portfolio with the opportunity to licence agents in pre-clinical to Phase II clinical development.
View all ›Medical Devices
Our non-invasive medical device - High Intensity Focus Ultrasound - is available for investment or collaboration.
View all ›Biomarkers
Screening, prognostic, predictive and diagnostic biomarkers. Non-invasive and tissue based cancer biomarkers - available for licensing or collaborative development.
View all ›Enabling Technology
Platform technology and research tool opportunities for use in a range of therapeutic and diagnostic applications - available for licensing.
View all ›Research Tools Portfolio
A large portfolio of monoclonal and polyclonal antibodies as well as cell lines and transgenic mice models - Available for purchase and licensing as research use only or in vitro diagnostics.
View all ›